- $717.32m
- $569.96m
Candel's cancer therapy meets late-stage trial goal, shares soar (updated)
Candel surges as prostate cancer therapy meets main goal of late-stage study
Candel Therapeutics' cancer drug meets late-stage trial goals
Brief: Candel Therapeutics Q3 Net Income USD -10.646 Million
Brief: Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa To Its Board
Brief: Candel Therapeutics Q2 Net Income USD -22.237 Million
Brief: Candel Therapeutics To Join Russell 3000® Index
U.S. STOCKS ON THE MOVE-HP, Salesforce, C3.ai
Candel Therapeutics rises on orphan drug tag for glioma treatment
U.S. STOCKS ON THE MOVE-Gold miners, Dell, Nutanix
U.S. STOCKS ON THE MOVE-XPO, Howmet Aerospace, Martin Midstream
U.S. STOCKS ON THE MOVE-Guardant Health, Lucid, Shift4 Payments
U.S. STOCKS ON THE MOVE-Iovance Biotherapeutics, The9, Guardant Health
Candel jumps on positive mid-stage trial data for lung cancer treatment
Brief: Candel Therapeutics Q1 Net Income USD -8.221 Million
U.S. STOCKS ON THE MOVE-Rent the Runway, Lumen Technologies, Enliven Therapeutics
U.S. STOCKS ON THE MOVE-Constellation Brands, Nike, Rocket Lab
Brief: Candel Therapeutics Receives FDA Orphan Drug Designation For CAN-2409 For Treatment Of Pancreatic Cancer
Candel Therapeutics jumps on orphan drug tag for lead cancer therapy